BY MARKETWIRE
-
Genmab’s cancer drug shows positive results against Richter transformation
Genmab has actually established the antibody therapy Epcoritamab in cooperation with Abbvie.
-
Eli Lilly obtains subsidy coverage for diabetes drug in China
Novo Nordisk’s Ozempic has actually been qualified for aids on the Chinese market given that 2022.
-
Novo Nordisk ready for December launch of Ozempic in India
After China, India has one of the most diabetics on earth. At the exact same time, the nation is experiencing fast development in the variety of obese individuals.
-
Novo Nordisk CFO to major German bank: Many headwinds ahead in 2026
German banks Berenberg anticipates Novo Nordisk to provide adverse profits development of 2% following year, in addition to adverse development in revenues per share of 7%.
-
Novo Nordisk greenlighted by German antitrust authorities to acquire Akero
Novo Nordisk introduced the procurement of Akero in very early October of this year.
-
Citigroup sees positive growth in all three GN divisions next year
GN is not anticipated to encounter as much affordable stress from US-based Starkey as it did when Sonova started offering its items in the Costco grocery store chain this summertim…
-
Costco tests sales of Starkey hearing aids – prospects for increased competition again
United States business Starkey ends up being Costco’s 5th listening device vendor.
-
Novo Nordisk to investigate cagrisema in children and adolescents in new study
The research is readied to start in January and will certainly consist of 460 youngsters and youths to the age of 8, with individuals to be hired via 97 screening facilities in Chi…
-
Demant focuses on its own products for KIND: Difficult to do much about fixed costs
Niels Wagner and a tiny delegation remain in Germany to present Demant’s innovation and method, containing developing harmonies by phasing in Demant’s innovation under …
-
Sydbank on Bavarian Nordic: positive signal in share buyback
The Danish financial institution claims that this can enhance depend on in between investors and monitoring.